SIGA TECHNOLOGIES INC (SIGA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, SIGA TECHNOLOGIES INC's filing signal turned negative.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the development and sale of TPOXX(R), an antiviral drug for the treatment of human smallpox disease. The company primarily sells TPOXX(R) (both oral and intravenous formulations) to the U.S. Government and international governments, with significant revenue derived from a contract with the Biomedical Advanced Research and Development Authority (BARDA). TPOXX(R) has received FDA approval for smallpox treatment and has also gained regulatory approval in Europe, Canada, the UK, and Japan for smallpox, mpox, cowpox, and vaccinia complications, though its mpox indication is under review for potential withdrawal in Europe. SIGA relies on third-party contract manufacturing organizations for production and does not have its own manufacturing infrastructure.

Primary revenue drivers are sales of TPOXX(R) (oral and intravenous formulations) to the U.S. Government under the BARDA contract, and to a lesser extent, international government sales. Revenue is also generated from research and development activities under government contracts.